Skip to main content
Atrás
HAE logo

Haemonetics Corporation

Calidad de datos: 100%
HAE
NYSE Healthcare Medical - Instruments & Supplies
$58.46
▼ $0.12 (-0.20%)
Cap. Mercado: 2.74B
Rango del Día
$58.43 $59.99
Rango de 52 Semanas
$47.32 $87.32
Volumen
307,419
Promedio 50D / 200D
$65.06 / $65.66
Cierre Anterior
$58.58

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E 16.3 0.4
P/B 3.3 2.9
ROE % 18.8 3.8
Net Margin % 12.3 3.9
Rev Growth 5Y % 11.8 10.0
D/E 1.5 0.2

Precio Objetivo de Analistas

Hold
$86.60 +48.1%
Low: $80.00 High: $94.00
P/E Futuro
11.8
EPS Futuro
$4.95
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
1.3 B

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $7.66
$7.54 – $7.76
1.8 B 3
FY2029 $6.90
$6.79 – $6.99
1.6 B 3
FY2028 $5.93
$5.52 – $6.17
1.5 B 5

Puntos Clave

Revenue grew 11.82% annually over 5 years — strong growth
Earnings grew 42.64% over the past year
ROE of 18.83% — decent returns on equity
Generating 142.45M in free cash flow
PEG of 0.44 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 7.87%

Crecimiento

Revenue Growth (5Y)
11.82%
Revenue (1Y)3.95%
Earnings (1Y)42.64%
FCF Growth (3Y)-6.48%

Calidad

Return on Equity
18.83%
ROIC8.13%
Net Margin12.32%
Op. Margin16.30%

Seguridad

Debt / Equity
1.49
Current Ratio1.62
Interest Coverage22.76

Valoración

P/E Ratio
16.32
P/B Ratio3.33
EV/EBITDA16.48
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3.95% Revenue Growth (3Y) 7.91%
Earnings Growth (1Y) 42.64% Earnings Growth (3Y) 20.54%
Revenue Growth (5Y) 11.82% Earnings Growth (5Y) 20.52%
Profitability
Revenue (TTM) 1.36B Net Income (TTM) 167.68M
ROE 18.83% ROA 6.84%
Gross Margin 57.21% Operating Margin 16.30%
Net Margin 12.32% Free Cash Flow (TTM) 142.45M
ROIC 8.13% FCF Growth (3Y) -6.48%
Safety
Debt / Equity 1.49 Current Ratio 1.62
Interest Coverage 22.76 Dividend Yield 0.00%
Valuation
P/E Ratio 16.32 P/B Ratio 3.33
P/S Ratio 2.01 PEG Ratio 0.44
EV/EBITDA 16.48 Dividend Yield 0.00%
Market Cap 2.74B Enterprise Value 3.65B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.36B 1.31B 1.17B 993.20M 870.46M
Net Income 167.68M 117.56M 115.40M 43.38M 79.47M
EPS (Diluted) 3.31 2.29 2.24 0.84 1.55
Gross Profit 778.55M 711.92M 622.87M 530.77M 428.45M
Operating Income 221.82M 164.88M 156.03M 80.75M 89.75M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2.45B 2.20B 1.93B 1.86B 1.82B
Total Liabilities 1.63B 1.24B 1.12B 1.11B 1.09B
Shareholders' Equity 820.84M 959.96M 818.00M 749.42M 731.67M
Total Debt 1.22B 807.79M 765.89M 780.79M 778.28M
Cash & Equivalents 306.76M 178.80M 284.47M 259.50M 192.31M
Current Assets 934.98M 768.90M 769.72M 756.03M 693.55M
Current Liabilities 578.11M 300.38M 251.82M 442.27M 253.50M

Puntuaciones de Estrategias

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#145 of 326
54

Actividad Reciente

Entró Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026